Cambridge-based start-up Lucida Medical has received Class IIb CE certification for its AI-based prostate cancer detection software, Prostate Intelligence™ (Pi™).
This certification allows the software to be used in Europe and aims to improve cancer diagnosis. A clinical study revealed that MRI can miss 12% of significant prostate cancers and refer 55% of individuals without significant cancer for unnecessary biopsies.
Pi™, utilising AI, integrates with radiologists' workflow to enhance diagnostic accuracy, reduce radiologist time, and decrease avoidable biopsies. It automatically produces 3D segmentations, volumes, and risk scores, potentially reducing undetected cancers to 6% and avoidable biopsies to 43%.
With prostate cancer being the most common cancer in men, earlier detection can lead to improved patient outcomes and life expectancy.
The CEO and Co-Founder of Lucida Medical see Pi™ as a leading platform for prostate cancer diagnosis, integrating with radiologists' workflows and demonstrating exceptional real-world accuracy, which can enhance patient outcomes and reduce healthcare costs.
Click here to read the original news story.